80 participants
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-13
- Start Date:
- 2026-11-01
- Completion:
- 2029-12-30
Conditions
- Relapsed/Refractory B-cell Malignancies
Interventions
- BIOLOGICAL
No Results Yet